Reliability of the vestibular evoked myogenic potential test in assessing intratympanic gentamicin therapy in Meniere's disease.

نویسندگان

  • Levent N Ozluoglu
  • Guzin Akkuzu
  • Nuri Ozgirgin
  • Erkan Tarhan
چکیده

CONCLUSIONS The results of this preliminary study demonstrate that with regard to determining the efficacy of intratympanic (IT) gentamicin treatment in patients with Meniere's disease, the reliability of testing for vestibular evoked myogenic potentials (VEMPs) is comparable to that of caloric tests. Compared with caloric tests, VEMP measurements are more comfortable and take less time. The results of VEMP and caloric testing do not correlate with the results of hearing tests. OBJECTIVE To test the reliability of VEMP testing to monitor the results of IT gentamicin therapy in patients with Meniere's disease. SUBJECTS AND METHODS Twelve patients with unilateral Meniere's disease were evaluated with pure tone audiometry (PTA), bithermal caloric tests, and VEMP tests. Patients with measurable caloric and VEMP results before IT gentamicin treatment were included in the study. IT gentamicin (0.5 ml) at a concentration of 40 mg/ml was administered to the patients. Reinjection was performed 10 days later depending on patients' complaints. Patients were re-evaluated with short- and long-term VEMP, hearing, and caloric test results. RESULTS Caloric responses and VEMPs changed following gentamicin therapy in 9 patients and 12 patients, respectively. Long-term results of caloric and VEMP tests in patients receiving IT gentamicin treatment changed in 7 patients and 10 patients, respectively.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

One-shot, low-dosage intratympanic gentamicin for Ménière's disease: Clinical, posturographic and vestibular test findings

BACKGROUND Ménière's disease has been remained as a difficult therapeutic challenge. The present study aimed to determine the effects of one-shot low-dosage intratympanic gentamicin on vertigo control, auditory outcomes and findings of computerized dynamic posturography and vestibular evoked myogenic potentials in patients with unilateral Ménière's disease. METHODS In a prospective clinical s...

متن کامل

Cervical and ocular vestibular evoked myogenic potentials in multiple sclerosis participants

  Background: Multiple sclerosis (MS) is a chronic neurological disease that affects brain and spinal cord. The infratentorial region contains the cerebellum and brainstem. Vestibular evoked myogenic potentials (VEMPs) are short-latency myogenic responses. Cervical vestibular evoked myogenic potential (cVEMP) is a manifestation of vestibulocolic reflex and ocular vestibular evoked myogenic pote...

متن کامل

Vestibular evoked myogenic potentials in patients with rheumatoid arthritis

  Background: Rheumatoid arthritis (RA) is an autoimmune systemic disease. Most common autoimmune diseases are multisystem disorders that may also present with otological manifestations, and autoimmune inner ear disease accompanied by vestibular dysfunction. This study aimed to compare the vestibular function between RA patients and normal subjects using cervical vestibular evoked myogenic...

متن کامل

Characteristics and clinical applications of vestibular-evoked myogenic potentials.

A recent technique of assessing vestibular function, the vestibular-evoked myogenic potential (VEMP), is an otolith-mediated, short-latency reflex recorded from averaged sternocleidomastoid electromyography in response to intense auditory clicks delivered via headphones. Since their first description 10 years ago, VEMPs are now being used by investigators worldwide, and characteristic changes o...

متن کامل

Intratympanic gentamicin for the treatment of Meniere's disease and other forms of peripheral vertigo.

Titration therapy with intratympanic gentamicin offers class A or B control of vertigo in 87% (range, 75%-100%) of patients with unilateral Ménière's disease. The risk of additional hearing loss is about 21% (range,0-37%). Vertigo may recur, however, in nearly one third of patients over time. These recurrences can also be treated by intratympanic gentamicin with a similar risk of hearing loss. ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Acta oto-laryngologica

دوره 128 4  شماره 

صفحات  -

تاریخ انتشار 2008